Exiris makes use of several platform technologies for target identification and validation. In addition, Exiris is developing its own antibody and drug conjugate technologies: Cancer stem cell platform, Drug conjugate technology and Antibody technologies.

read more


Exiris provides contract research services and collaborative development agreements using its innovative technology platforms: CSC Platform, Target ID, Drug-Conjugate platform, Custom human mAb production, Biomarker discovery and (…)

read more

Exiris @ Presa Diretta

Presa Diretta, the broadcast reporting on the Italian hottest news, interviews Exiris CSO on pharmaceutical research and drugs costs, and on the potential spreading benefits.. Read More →

Contact us

Exiris srl

Via Giano Della Bella 34
00162 Roma

Legal address:
Via Savona 6
00182 Rome – Italy

+39 06 49904451
+39 06 49904457